Special Episode: Daridorexant Approved for Insomnia
Jan 11, 2022, 12:00 AM
Welcome to this special episode of the NeurologyLive® Mind Moments™ podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In 2022 and onward, whenever the FDA makes a major decision for the field of neurology, we'll be releasing short special episodes to offer a snapshot of the news, including the main takeaways for the clinical community, as well as highlights of the efficacy and safety profile of the agent in question.
In this episode, we're covering the recent approval of daridorexant (Quviviq; Idorsia) for the treatment of insomnia. Offering commentary is Thomas Roth, PhD, director, Sleep Disorders and Research Center, Henry Ford Hospital; professor of psychiatry, Wayne State University School of Medicine; and clinical professor of psychiatry, University of Michigan College of Medicine; and an investigator in the clinical development studies.
In this episode, we're covering the recent approval of daridorexant (Quviviq; Idorsia) for the treatment of insomnia. Offering commentary is Thomas Roth, PhD, director, Sleep Disorders and Research Center, Henry Ford Hospital; professor of psychiatry, Wayne State University School of Medicine; and clinical professor of psychiatry, University of Michigan College of Medicine; and an investigator in the clinical development studies.
For more of NeurologyLive®'s coverage of daridorexant's approval, head here: FDA Approves Daridorexant for Insomnia Treatment.
For more coverage of sleep disorders, head to NeurologyLive®'s Sleep Medicine clinical focus page.
For more coverage of sleep disorders, head to NeurologyLive®'s Sleep Medicine clinical focus page.
Episode Breakdown:
- 0:30 – Daridorexant (Quviviq; Idorsia) approved for insomnia
- 2:20 – Thomas Roth, PhD, with the clinical takeaways
- 4:30 – Efficacy data from Study 1 and Study 2
- 6:10 – Thomas Roth, PhD, on the efficacy profile
- 8:20 – Safety data from Study 1 and Study 2
- 9:00 – Thomas Roth, PhD, on the safety profile
Thanks for listening to the NeurologyLive® Mind Moments™ podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.
REFERENCE
Idorsia receives US FDA approval of Quviviq (daridorexant) 25 and 50 mg for the treatment of adults with insomnia. News release. Idorsia. January 10, 2022. Accessed January 10, 2022. https://www.biospace.com/article/releases/idorsia-receives-us-fda-approval-of-quviviq-daridorexant-25-and-50-mg-for-the-treatment-of-adults-with-insomnia/
Idorsia receives US FDA approval of Quviviq (daridorexant) 25 and 50 mg for the treatment of adults with insomnia. News release. Idorsia. January 10, 2022. Accessed January 10, 2022. https://www.biospace.com/article/releases/idorsia-receives-us-fda-approval-of-quviviq-daridorexant-25-and-50-mg-for-the-treatment-of-adults-with-insomnia/